Dow Jones

39 118,86

-0,12%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

NK

NantKwest (NK)

NantKwest Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:NK

1 2 3 4 5 6 7 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
16/06/2023	23h46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:NK	NantKwest Inc
14/06/2023	23h15	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:NK	NantKwest Inc
23/05/2023	12h01	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:NK	NantKwest Inc
28/04/2023	22h34	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:NK	NantKwest Inc
28/04/2023	22h31	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:NK	NantKwest Inc
16/02/2023	12h04	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:NK	NantKwest Inc
10/02/2023	12h11	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:NK	NantKwest Inc
12/12/2022	13h13	Edgar (US Regulatory)	Registration of Additional Securities (up to 20%) (s-3mef)	NASDAQ:NK	NantKwest Inc
09/11/2022	12h10	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:NK	NantKwest Inc
18/05/2022	12h08	Edgar (US Regulatory)	Withdrawal of Registration Statement (ammendment) (aw)	NASDAQ:NK	NantKwest Inc
18/05/2022	12h06	Edgar (US Regulatory)	Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex)	NASDAQ:NK	NantKwest Inc
16/05/2022	12h07	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3/a)	NASDAQ:NK	NantKwest Inc
01/03/2022	22h35	Edgar (US Regulatory)	Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)	NASDAQ:NK	NantKwest Inc
28/01/2022	22h29	Edgar (US Regulatory)	Annual Statement of Changes in Beneficial Ownership (5)	NASDAQ:NK	NantKwest Inc
30/12/2021	12h09	Edgar (US Regulatory)	Proxy Statement - Other Information (preliminary) (pre 14c)	NASDAQ:NK	NantKwest Inc
18/11/2021	15h01	Business Wire	Haeggquist & Eck, LLP Announces Investigation Regarding Whether PennyMac Required Home Owners to Purchase Excess Homeowners’ Insurance for Home Loans and Home Loan Refinancing	NASDAQ:NK	NantKwest Inc
12/11/2021	23h09	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:NK	NantKwest Inc
21/05/2021	23h12	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:NK	NantKwest Inc
21/05/2021	23h09	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:NK	NantKwest Inc
30/04/2021	23h26	Edgar (US Regulatory)	Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)	NASDAQ:NK	NantKwest Inc
22/04/2021	22h08	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:NK	NantKwest Inc
09/03/2021	22h15	Business Wire	ImmunityBio and NantKwest Complete Merger	NASDAQ:NK	NantKwest Inc
08/03/2021	22h30	Business Wire	Stockholders of NantKwest Approve Merger With ImmunityBio	NASDAQ:NK	NantKwest Inc
08/03/2021	15h00	Business Wire	ImmunityBio & NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Af...	NASDAQ:NK	NantKwest Inc
04/03/2021	22h13	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:NK	NantKwest Inc
02/03/2021	22h45	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:NK	NantKwest Inc
25/02/2021	01h26	Business Wire	All Three Independent Proxy Advisory Firms – ISS, Glass Lewis & Egan-Jones – Recommend NantKwest Stockholders Vote “FOR...	NASDAQ:NK	NantKwest Inc
24/02/2021	15h00	Business Wire	ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors	NASDAQ:NK	NantKwest Inc
16/02/2021	15h00	Business Wire	ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Inv...	NASDAQ:NK	NantKwest Inc
12/02/2021	00h13	Business Wire	ImmunityBio & NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Ora...	NASDAQ:NK	NantKwest Inc